全体要約
2023年の世界の軟部肉腫標的薬市場は、2030年までに成長が見込まれています。市場は地域別、セクター別に分けられ、2024年から2030年の予測売上が分析されています。アメリカ、中国、ヨーロッパの市場はそれぞれ成長が見込まれ、主要企業にはロシュ、ファイザー、ジョンソン・エンド・ジョンソンなどが含まれています。
このレポートは、軟部肉腫標的薬市場の製品タイプ、アプリケーション、主要プレイヤー、地域別の成長機会を包括的に示しています。市場はローカル肉腫、転移性肉腫、その他の肉腫に分類され、病院や腫瘍センターでの利用が主なアプリケーションです。
関連する質問
Roche, Pfizer, Johnson & Johnson, GSK Plc, Teva Pharmaceuticals, Celgene, Bristol Myers Squibb, BeiGene, Shenzhen Chipscreen, Monopar Therapeutics, Akeso Biopharma
製品セグメンテーションのトレンド, 地域別市場シェアの変化, 主要企業の戦略的動向
概要
LPI (LP Information)の最新の研究報告書「軟部組織肉腫ターゲット薬の産業予測」では、過去の売上を調査し、2023年の世界の軟部組織肉腫ターゲット薬の売上をレビューし、2024年から2030年までの予測された軟部組織肉腫ターゲット薬の売上を地域別及び市場セクター別に包括的に分析しています。地域、市場セクター、サブセクター別に区分された軟部組織肉腫ターゲット薬の売上をもとに、この報告書は世界の軟部組織肉腫ターゲット薬産業の詳細な分析を百万USドル単位で提供。
このインサイトレポートは、世界的な軟部腫瘍肉腫ターゲット薬市場の包括的な分析を提供し、製品セグメンテーション、企業形成、収益、市場シェア、最新の開発、M&A活動に関連する主要なトレンドを強調しています。このレポートでは、軟部腫瘍肉腫ターゲット薬のポートフォリオや能力、市場参入戦略、市場ポジション、地理的なフットプリントに焦点を当て、主要なグローバル企業の戦略も分析し、加速する世界の軟部腫瘍肉腫ターゲット薬市場におけるこれらの企業の独自の立ち位置をよりよく理解するためのものです。
このインサイトレポートは、軟部組織肉腫標的薬の世界的な見通しを形成する主要な市場トレンド、推進要因、および影響要因を評価し、種類、用途、地域、市场規模による予測を分解して、新たな機会のポケットを強調します。何百ものボトムアップの定性的および定量的市場データに基づく透明な方法論を用いたこの研究の予測は、世界の軟部組織肉腫標的薬の現在の状態と今後の軌道について非常に詳細な見解を提供します。
アメリカの軟部組織肉腫を対象とした薬剤市場は、2023年のXX米ドルから2030年までにXX米ドルに増加すると予測されています。2024年から2030年までの年平均成長率はXX%、です。
中国における軟部組織サルコーマ治療薬市場は、2023年のXX米ドルから2030年にはXX米ドルに増加することが見込まれており、2024年から2030年までの年平均成長率（CAGR）はXX%です。
ヨーロッパにおける軟部組織肉腫向けターゲット薬の市場は、2023年のXX米ドルから2030年までにXX米ドルへと増加することが見込まれており、2024年から2030年までのCAGRはXX%です。
グローバルな主要な軟部動腫瘍標的薬のプレーヤーには、ロシュ、ファイザー、ジョンソン・エンド・ジョンソン、GSK Plc、テバファーマシューティカルズなどが含まれます。収益の面では、2023年において、世界の2大企業がほぼXX%のシェアを占めました。
この報告書では、ソフトティッシュサルコーマ標的薬市場の製品タイプ、アプリケーション、主要プレーヤー、主要地域および国ごとの包括的な概要、市場シェア、および成長機会を提示します。
タイプ別セグメンテーション
局所肉腫
転移性サルコーマ
その他の肉腫
アプリケーションによるセグメンテーション
病院
腫瘍学センター
その他
このレポートは地域別に市場を分けています：
アメリカ大陸
アメリカ合衆国
カナダ
メキシコ
ブラジル
アジア太平洋地域
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
ロシア
中東およびアフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下のプロファイルに掲載された企業は、主要な専門家から収集した情報と、企業のカバレッジ、製品ポートフォリオ、市場浸透率を分析した結果に基づいて選定されています。
ロシュ
ファイザー
ジョンソン・エンド・ジョンソン
GSK plc
テバ製薬
セルジーン
ブリストル・マイヤーズ スクイブ
ベイジーン
深圳チップスクリン
モノパー・セラピューティクス
アケソバイオファーマ
※以下の目次にて、具体的なレポートの構成をご覧頂けます。ご購入、無料サンプルご請求、その他お問い合わせは、ページ上のボタンよりお進みください。
目次
1 調査範囲
1.1 市場イントロダクション
1.2 対象年
1.3 調査目的
1.4 市場調査手法
1.5 調査プロセスとデータソース
1.6 経済指標
1.7 通貨
1.8 市場予測における留意事項
2 エグゼクティブサマリー
2.1 世界市場概要
2.1.1 グローバルの軟部肉腫標的薬市場規模、（2019年～2030年）
2.1.2 軟部肉腫標的薬市場規模、CAGR（地域別）（2019年 vs 2023年 vs 2030年）
2.2 軟部肉腫標的薬セグメント、タイプ別
2.2.1 局所肉腫
2.2.2 転移性肉腫
2.2.3 その他の肉腫
2.3 軟部肉腫標的薬市場規模：タイプ別
2.3.1 軟部肉腫標的薬市場規模、CAGR（タイプ別）（2019年 vs 2023年 vs 2030年）
2.3.2 グローバルの軟部肉腫標的薬市場規模、市場シェア（タイプ別）（2019年～2024年）
2.4 軟部肉腫標的薬セグメント、用途別
2.4.1 病院
2.4.2 オンコロジーセンター
2.4.3 その他
2.5 軟部肉腫標的薬市場規模：用途別
2.5.1 軟部肉腫標的薬市場規模、CAGR（用途別）（2019年 vs 2023年 vs 2030年）
2.5.2 グローバルの軟部肉腫標的薬市場規模、市場シェア（用途別）（2019年～2024年）
3 軟部肉腫標的薬市場規模：プレイヤー別
3.1 軟部肉腫標的薬市場規模、市場シェア（プレイヤー別）
3.1.1 グローバルにおける軟部肉腫標的薬市場の収益規模、プレイヤー別（2019年～2024年）
3.1.2 グローバルにおける軟部肉腫標的薬市場の収益シェア、プレイヤー別（2019年～2024年）
3.2 グローバルの軟部肉腫標的薬市場キープレイヤー拠点および提供製品
3.3 市場集中度分析
3.3.1 競合情勢分析
3.3.2 集中度レシオ（CR3、CR5、CR10）（2022年～2024年）
3.4 新製品・潜在的参入
3.5 M&A、拡大
4 軟部肉腫標的薬、地域別
4.1 軟部肉腫標的薬市場規模（地域別）（2019年～2024年）
4.2 アメリカズにおける軟部肉腫標的薬市場規模成長（2019年〜2024年）
4.3 APACにおける軟部肉腫標的薬市場規模成長（2019年〜2024年）
4.4 ヨーロッパにおける軟部肉腫標的薬市場規模成長（2019年〜2024年）
4.5 中東・アフリカにおける軟部肉腫標的薬市場規模成長（2019年〜2024年）
5 アメリカズ
5.1 アメリカズにおける軟部肉腫標的薬市場規模、国別（2019年〜2024年）
5.2 アメリカズにおける軟部肉腫標的薬市場規模、タイプ別（2019年〜2024年）
5.3 アメリカズにおける軟部肉腫標的薬市場規模、用途別（2019年〜2024年）
5.4 米国
5.5 カナダ
5.6 メキシコ
5.7 ブラジル
6 APAC
6.1 APACにおける軟部肉腫標的薬市場規模、地域別（2019年〜2024年）
6.2 APACにおける軟部肉腫標的薬市場規模、タイプ別（2019年〜2024年）
6.3 APACにおける軟部肉腫標的薬市場規模、用途別（2019年〜2024年）
6.4 中国
6.5 日本
6.6 韓国
6.7 東南アジア
6.8 インド
6.9 オーストラリア
7 ヨーロッパ
7.1 ヨーロッパの軟部肉腫標的薬 国別（2019年～2024年）
7.2 ヨーロッパにおける軟部肉腫標的薬市場規模、タイプ別（2019年〜2024年）
7.3 ヨーロッパにおける軟部肉腫標的薬市場規模、用途別（2019年〜2024年）
7.4 ドイツ
7.5 フランス
7.6 英国
7.7 イタリア
7.8 ロシア
8 中東・アフリカ
8.1 中東・アフリカの軟部肉腫標的薬 地域別（2019年～2024年）
8.2 中東・アフリカにおける軟部肉腫標的薬市場規模、タイプ別（2019年〜2024年）
8.3 中東・アフリカにおける軟部肉腫標的薬市場規模、用途別（2019年〜2024年）
8.4 エジプト
8.5 南アフリカ
8.6 イスラエル
8.7 トルコ
8.8 GCC地域
9 市場ドライバー・課題・トレンド
9.1 市場ドライバー・成長機会
9.2 市場課題・リスク
9.3 業界トレンド
10 グローバルの軟部肉腫標的薬市場、市場予測
10.1 グローバルの軟部肉腫標的薬、市場予測（地域別）（2025年～2030年）
10.1.1 グローバルの軟部肉腫標的薬、市場予測（地域別）（2025年～2030年）
10.1.2 アメリカズの軟部肉腫標的薬、市場予測
10.1.3 APACの軟部肉腫標的薬、市場予測
10.1.4 ヨーロッパの軟部肉腫標的薬、市場予測
10.1.5 中東・アフリカの軟部肉腫標的薬、市場予測
10.2 アメリカズの軟部肉腫標的薬、市場予測（国別）（2025年～2030年）
10.3 APACの軟部肉腫標的薬、市場予測（地域別）（2025年～2030年）
10.4 ヨーロッパの軟部肉腫標的薬、市場予測（国別）（2025年～2030年）
10.5 中東・アフリカの軟部肉腫標的薬、市場予測（地域別）（2025年～2030年）
10.6 グローバルの軟部肉腫標的薬、市場予測（タイプ別）（2025年～2030年）
10.7 グローバルの軟部肉腫標的薬、市場予測（用途別）（2025年～2030年）
11 キープレイヤー分析
11.1 Roche
11.1.1 Roche：企業情報
11.1.2 Roche：軟部肉腫標的薬分野の提供製品
11.1.3 Roche：軟部肉腫標的薬収益・グロスマージンおよび市場シェア（2019年～2024年）
11.1.4 Roche：主要事業概要
11.1.5 Roche：直近の展開
11.2 Pfizer
11.2.1 Pfizer：企業情報
11.2.2 Pfizer：軟部肉腫標的薬分野の提供製品
11.2.3 Pfizer：軟部肉腫標的薬収益・グロスマージンおよび市場シェア（2019年～2024年）
11.2.4 Pfizer：主要事業概要
11.2.5 Pfizer：直近の展開
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson：企業情報
11.3.2 Johnson & Johnson：軟部肉腫標的薬分野の提供製品
11.3.3 Johnson & Johnson：軟部肉腫標的薬収益・グロスマージンおよび市場シェア（2019年～2024年）
11.3.4 Johnson & Johnson：主要事業概要
11.3.5 Johnson & Johnson：直近の展開
11.4 GSK Plc
11.4.1 GSK Plc：企業情報
11.4.2 GSK Plc：軟部肉腫標的薬分野の提供製品
11.4.3 GSK Plc：軟部肉腫標的薬収益・グロスマージンおよび市場シェア（2019年～2024年）
11.4.4 GSK Plc：主要事業概要
11.4.5 GSK Plc：直近の展開
11.5 Teva Pharmaceuticals
11.5.1 Teva Pharmaceuticals：企業情報
11.5.2 Teva Pharmaceuticals：軟部肉腫標的薬分野の提供製品
11.5.3 Teva Pharmaceuticals：軟部肉腫標的薬収益・グロスマージンおよび市場シェア（2019年～2024年）
11.5.4 Teva Pharmaceuticals：主要事業概要
11.5.5 Teva Pharmaceuticals：直近の展開
11.6 Celgene
11.6.1 Celgene：企業情報
11.6.2 Celgene：軟部肉腫標的薬分野の提供製品
11.6.3 Celgene：軟部肉腫標的薬収益・グロスマージンおよび市場シェア（2019年～2024年）
11.6.4 Celgene：主要事業概要
11.6.5 Celgene：直近の展開
11.7 Bristol Myers Squibb
11.7.1 Bristol Myers Squibb：企業情報
11.7.2 Bristol Myers Squibb：軟部肉腫標的薬分野の提供製品
11.7.3 Bristol Myers Squibb：軟部肉腫標的薬収益・グロスマージンおよび市場シェア（2019年～2024年）
11.7.4 Bristol Myers Squibb：主要事業概要
11.7.5 Bristol Myers Squibb：直近の展開
11.8 BeiGene
11.8.1 BeiGene：企業情報
11.8.2 BeiGene：軟部肉腫標的薬分野の提供製品
11.8.3 BeiGene：軟部肉腫標的薬収益・グロスマージンおよび市場シェア（2019年～2024年）
11.8.4 BeiGene：主要事業概要
11.8.5 BeiGene：直近の展開
11.9 Shenzhen Chipscreen
11.9.1 Shenzhen Chipscreen：企業情報
11.9.2 Shenzhen Chipscreen：軟部肉腫標的薬分野の提供製品
11.9.3 Shenzhen Chipscreen：軟部肉腫標的薬収益・グロスマージンおよび市場シェア（2019年～2024年）
11.9.4 Shenzhen Chipscreen：主要事業概要
11.9.5 Shenzhen Chipscreen：直近の展開
11.10 Monopar Therapeutics
11.10.1 Monopar Therapeutics：企業情報
11.10.2 Monopar Therapeutics：軟部肉腫標的薬分野の提供製品
11.10.3 Monopar Therapeutics：軟部肉腫標的薬収益・グロスマージンおよび市場シェア（2019年～2024年）
11.10.4 Monopar Therapeutics：主要事業概要
11.10.5 Monopar Therapeutics：直近の展開
11.11 Akeso Biopharma
11.11.1 Akeso Biopharma：企業情報
11.11.2 Akeso Biopharma：軟部肉腫標的薬分野の提供製品
11.11.3 Akeso Biopharma：軟部肉腫標的薬収益・グロスマージンおよび市場シェア（2019年～2024年）
11.11.4 Akeso Biopharma：主要事業概要
11.11.5 Akeso Biopharma：直近の展開
12 調査の結果・結論
※英文のレポートについての日本語表記のタイトルや紹介文などは、すべて生成AIや自動翻訳ソフトを使用して提供しております。それらはお客様の便宜のために提供するものであり、当社はその内容について責任を負いかねますので、何卒ご了承ください。適宜英語の原文をご参照ください。
“All Japanese titles, abstracts, and other descriptions of English-language reports were created using generative AI and/or machine translation. These are provided for your convenience only and may contain errors and inaccuracies. Please be sure to refer to the original English-language text. We disclaim all liability in relation to your reliance on such AI-generated and/or machine-translated content.”
Description
LPI (LP Information)' newest research report, the “Soft Tissue Sarcoma Targeted Drugs Industry Forecast” looks at past sales and reviews total world Soft Tissue Sarcoma Targeted Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected Soft Tissue Sarcoma Targeted Drugs sales for 2024 through 2030. With Soft Tissue Sarcoma Targeted Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Soft Tissue Sarcoma Targeted Drugs industry.
This Insight Report provides a comprehensive analysis of the global Soft Tissue Sarcoma Targeted Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Soft Tissue Sarcoma Targeted Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Soft Tissue Sarcoma Targeted Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Soft Tissue Sarcoma Targeted Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Soft Tissue Sarcoma Targeted Drugs.
United States market for Soft Tissue Sarcoma Targeted Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Soft Tissue Sarcoma Targeted Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Soft Tissue Sarcoma Targeted Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Soft Tissue Sarcoma Targeted Drugs players cover Roche, Pfizer, Johnson & Johnson, GSK Plc and Teva Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Soft Tissue Sarcoma Targeted Drugs market by product type, application, key players and key regions and countries.
Segmentation by type
Local Sarcoma
Metastatic Sarcoma
Other Sarcoma
Segmentation by application
Hospitals
Oncology Centers
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Pfizer
Johnson & Johnson
GSK Plc
Teva Pharmaceuticals
Celgene
Bristol Myers Squibb
BeiGene
Shenzhen Chipscreen
Monopar Therapeutics
Akeso Biopharma
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Soft Tissue Sarcoma Targeted Drugs Market Size 2019-2030
2.1.2 Soft Tissue Sarcoma Targeted Drugs Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Soft Tissue Sarcoma Targeted Drugs Segment by Type
2.2.1 Local Sarcoma
2.2.2 Metastatic Sarcoma
2.2.3 Other Sarcoma
2.3 Soft Tissue Sarcoma Targeted Drugs Market Size by Type
2.3.1 Soft Tissue Sarcoma Targeted Drugs Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Soft Tissue Sarcoma Targeted Drugs Market Size Market Share by Type (2019-2024)
2.4 Soft Tissue Sarcoma Targeted Drugs Segment by Application
2.4.1 Hospitals
2.4.2 Oncology Centers
2.4.3 Other
2.5 Soft Tissue Sarcoma Targeted Drugs Market Size by Application
2.5.1 Soft Tissue Sarcoma Targeted Drugs Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Soft Tissue Sarcoma Targeted Drugs Market Size Market Share by Application (2019-2024)
3 Soft Tissue Sarcoma Targeted Drugs Market Size by Player
3.1 Soft Tissue Sarcoma Targeted Drugs Market Size Market Share by Players
3.1.1 Global Soft Tissue Sarcoma Targeted Drugs Revenue by Players (2019-2024)
3.1.2 Global Soft Tissue Sarcoma Targeted Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Soft Tissue Sarcoma Targeted Drugs Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Soft Tissue Sarcoma Targeted Drugs by Regions
4.1 Soft Tissue Sarcoma Targeted Drugs Market Size by Regions (2019-2024)
4.2 Americas Soft Tissue Sarcoma Targeted Drugs Market Size Growth (2019-2024)
4.3 APAC Soft Tissue Sarcoma Targeted Drugs Market Size Growth (2019-2024)
4.4 Europe Soft Tissue Sarcoma Targeted Drugs Market Size Growth (2019-2024)
4.5 Middle East & Africa Soft Tissue Sarcoma Targeted Drugs Market Size Growth (2019-2024)
5 Americas
5.1 Americas Soft Tissue Sarcoma Targeted Drugs Market Size by Country (2019-2024)
5.2 Americas Soft Tissue Sarcoma Targeted Drugs Market Size by Type (2019-2024)
5.3 Americas Soft Tissue Sarcoma Targeted Drugs Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Soft Tissue Sarcoma Targeted Drugs Market Size by Region (2019-2024)
6.2 APAC Soft Tissue Sarcoma Targeted Drugs Market Size by Type (2019-2024)
6.3 APAC Soft Tissue Sarcoma Targeted Drugs Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Soft Tissue Sarcoma Targeted Drugs by Country (2019-2024)
7.2 Europe Soft Tissue Sarcoma Targeted Drugs Market Size by Type (2019-2024)
7.3 Europe Soft Tissue Sarcoma Targeted Drugs Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Soft Tissue Sarcoma Targeted Drugs by Region (2019-2024)
8.2 Middle East & Africa Soft Tissue Sarcoma Targeted Drugs Market Size by Type (2019-2024)
8.3 Middle East & Africa Soft Tissue Sarcoma Targeted Drugs Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Soft Tissue Sarcoma Targeted Drugs Market Forecast
10.1 Global Soft Tissue Sarcoma Targeted Drugs Forecast by Regions (2025-2030)
10.1.1 Global Soft Tissue Sarcoma Targeted Drugs Forecast by Regions (2025-2030)
10.1.2 Americas Soft Tissue Sarcoma Targeted Drugs Forecast
10.1.3 APAC Soft Tissue Sarcoma Targeted Drugs Forecast
10.1.4 Europe Soft Tissue Sarcoma Targeted Drugs Forecast
10.1.5 Middle East & Africa Soft Tissue Sarcoma Targeted Drugs Forecast
10.2 Americas Soft Tissue Sarcoma Targeted Drugs Forecast by Country (2025-2030)
10.2.1 United States Soft Tissue Sarcoma Targeted Drugs Market Forecast
10.2.2 Canada Soft Tissue Sarcoma Targeted Drugs Market Forecast
10.2.3 Mexico Soft Tissue Sarcoma Targeted Drugs Market Forecast
10.2.4 Brazil Soft Tissue Sarcoma Targeted Drugs Market Forecast
10.3 APAC Soft Tissue Sarcoma Targeted Drugs Forecast by Region (2025-2030)
10.3.1 China Soft Tissue Sarcoma Targeted Drugs Market Forecast
10.3.2 Japan Soft Tissue Sarcoma Targeted Drugs Market Forecast
10.3.3 Korea Soft Tissue Sarcoma Targeted Drugs Market Forecast
10.3.4 Southeast Asia Soft Tissue Sarcoma Targeted Drugs Market Forecast
10.3.5 India Soft Tissue Sarcoma Targeted Drugs Market Forecast
10.3.6 Australia Soft Tissue Sarcoma Targeted Drugs Market Forecast
10.4 Europe Soft Tissue Sarcoma Targeted Drugs Forecast by Country (2025-2030)
10.4.1 Germany Soft Tissue Sarcoma Targeted Drugs Market Forecast
10.4.2 France Soft Tissue Sarcoma Targeted Drugs Market Forecast
10.4.3 UK Soft Tissue Sarcoma Targeted Drugs Market Forecast
10.4.4 Italy Soft Tissue Sarcoma Targeted Drugs Market Forecast
10.4.5 Russia Soft Tissue Sarcoma Targeted Drugs Market Forecast
10.5 Middle East & Africa Soft Tissue Sarcoma Targeted Drugs Forecast by Region (2025-2030)
10.5.1 Egypt Soft Tissue Sarcoma Targeted Drugs Market Forecast
10.5.2 South Africa Soft Tissue Sarcoma Targeted Drugs Market Forecast
10.5.3 Israel Soft Tissue Sarcoma Targeted Drugs Market Forecast
10.5.4 Turkey Soft Tissue Sarcoma Targeted Drugs Market Forecast
10.5.5 GCC Countries Soft Tissue Sarcoma Targeted Drugs Market Forecast
10.6 Global Soft Tissue Sarcoma Targeted Drugs Forecast by Type (2025-2030)
10.7 Global Soft Tissue Sarcoma Targeted Drugs Forecast by Application (2025-2030)
11 Key Players Analysis
11.1 Roche
11.1.1 Roche Company Information
11.1.2 Roche Soft Tissue Sarcoma Targeted Drugs Product Offered
11.1.3 Roche Soft Tissue Sarcoma Targeted Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Roche Main Business Overview
11.1.5 Roche Latest Developments
11.2 Pfizer
11.2.1 Pfizer Company Information
11.2.2 Pfizer Soft Tissue Sarcoma Targeted Drugs Product Offered
11.2.3 Pfizer Soft Tissue Sarcoma Targeted Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Pfizer Main Business Overview
11.2.5 Pfizer Latest Developments
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Information
11.3.2 Johnson & Johnson Soft Tissue Sarcoma Targeted Drugs Product Offered
11.3.3 Johnson & Johnson Soft Tissue Sarcoma Targeted Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Johnson & Johnson Main Business Overview
11.3.5 Johnson & Johnson Latest Developments
11.4 GSK Plc
11.4.1 GSK Plc Company Information
11.4.2 GSK Plc Soft Tissue Sarcoma Targeted Drugs Product Offered
11.4.3 GSK Plc Soft Tissue Sarcoma Targeted Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 GSK Plc Main Business Overview
11.4.5 GSK Plc Latest Developments
11.5 Teva Pharmaceuticals
11.5.1 Teva Pharmaceuticals Company Information
11.5.2 Teva Pharmaceuticals Soft Tissue Sarcoma Targeted Drugs Product Offered
11.5.3 Teva Pharmaceuticals Soft Tissue Sarcoma Targeted Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Teva Pharmaceuticals Main Business Overview
11.5.5 Teva Pharmaceuticals Latest Developments
11.6 Celgene
11.6.1 Celgene Company Information
11.6.2 Celgene Soft Tissue Sarcoma Targeted Drugs Product Offered
11.6.3 Celgene Soft Tissue Sarcoma Targeted Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Celgene Main Business Overview
11.6.5 Celgene Latest Developments
11.7 Bristol Myers Squibb
11.7.1 Bristol Myers Squibb Company Information
11.7.2 Bristol Myers Squibb Soft Tissue Sarcoma Targeted Drugs Product Offered
11.7.3 Bristol Myers Squibb Soft Tissue Sarcoma Targeted Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Bristol Myers Squibb Main Business Overview
11.7.5 Bristol Myers Squibb Latest Developments
11.8 BeiGene
11.8.1 BeiGene Company Information
11.8.2 BeiGene Soft Tissue Sarcoma Targeted Drugs Product Offered
11.8.3 BeiGene Soft Tissue Sarcoma Targeted Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 BeiGene Main Business Overview
11.8.5 BeiGene Latest Developments
11.9 Shenzhen Chipscreen
11.9.1 Shenzhen Chipscreen Company Information
11.9.2 Shenzhen Chipscreen Soft Tissue Sarcoma Targeted Drugs Product Offered
11.9.3 Shenzhen Chipscreen Soft Tissue Sarcoma Targeted Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Shenzhen Chipscreen Main Business Overview
11.9.5 Shenzhen Chipscreen Latest Developments
11.10 Monopar Therapeutics
11.10.1 Monopar Therapeutics Company Information
11.10.2 Monopar Therapeutics Soft Tissue Sarcoma Targeted Drugs Product Offered
11.10.3 Monopar Therapeutics Soft Tissue Sarcoma Targeted Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Monopar Therapeutics Main Business Overview
11.10.5 Monopar Therapeutics Latest Developments
11.11 Akeso Biopharma
11.11.1 Akeso Biopharma Company Information
11.11.2 Akeso Biopharma Soft Tissue Sarcoma Targeted Drugs Product Offered
11.11.3 Akeso Biopharma Soft Tissue Sarcoma Targeted Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Akeso Biopharma Main Business Overview
11.11.5 Akeso Biopharma Latest Developments
12 Research Findings and Conclusion
List of Tables Table 1. Soft Tissue Sarcoma Targeted Drugs Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions) Table 2. Major Players of Local Sarcoma Table 3. Major Players of Metastatic Sarcoma Table 4. Major Players of Other Sarcoma Table 5. Soft Tissue Sarcoma Targeted Drugs Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions) Table 6. Global Soft Tissue Sarcoma Targeted Drugs Market Size by Type (2019-2024) & ($ Millions) Table 7. Global Soft Tissue Sarcoma Targeted Drugs Market Size Market Share by Type (2019-2024) Table 8. Soft Tissue Sarcoma Targeted Drugs Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions) Table 9. Global Soft Tissue Sarcoma Targeted Drugs Market Size by Application (2019-2024) & ($ Millions) Table 10. Global Soft Tissue Sarcoma Targeted Drugs Market Size Market Share by Application (2019-2024) Table 11. Global Soft Tissue Sarcoma Targeted Drugs Revenue by Players (2019-2024) & ($ Millions) Table 12. Global Soft Tissue Sarcoma Targeted Drugs Revenue Market Share by Player (2019-2024) Table 13. Soft Tissue Sarcoma Targeted Drugs Key Players Head office and Products Offered Table 14. Soft Tissue Sarcoma Targeted Drugs Concentration Ratio (CR3, CR5 and CR10) & (2022-2024) Table 15. New Products and Potential Entrants Table 16. Mergers & Acquisitions, Expansion Table 17. Global Soft Tissue Sarcoma Targeted Drugs Market Size by Regions 2019-2024 & ($ Millions) Table 18. Global Soft Tissue Sarcoma Targeted Drugs Market Size Market Share by Regions (2019-2024) Table 19. Global Soft Tissue Sarcoma Targeted Drugs Revenue by Country/Region (2019-2024) & ($ millions) Table 20. Global Soft Tissue Sarcoma Targeted Drugs Revenue Market Share by Country/Region (2019-2024) Table 21. Americas Soft Tissue Sarcoma Targeted Drugs Market Size by Country (2019-2024) & ($ Millions) Table 22. Americas Soft Tissue Sarcoma Targeted Drugs Market Size Market Share by Country (2019-2024) Table 23. Americas Soft Tissue Sarcoma Targeted Drugs Market Size by Type (2019-2024) & ($ Millions) Table 24. Americas Soft Tissue Sarcoma Targeted Drugs Market Size Market Share by Type (2019-2024) Table 25. Americas Soft Tissue Sarcoma Targeted Drugs Market Size by Application (2019-2024) & ($ Millions) Table 26. Americas Soft Tissue Sarcoma Targeted Drugs Market Size Market Share by Application (2019-2024) Table 27. APAC Soft Tissue Sarcoma Targeted Drugs Market Size by Region (2019-2024) & ($ Millions) Table 28. APAC Soft Tissue Sarcoma Targeted Drugs Market Size Market Share by Region (2019-2024) Table 29. APAC Soft Tissue Sarcoma Targeted Drugs Market Size by Type (2019-2024) & ($ Millions) Table 30. APAC Soft Tissue Sarcoma Targeted Drugs Market Size Market Share by Type (2019-2024) Table 31. APAC Soft Tissue Sarcoma Targeted Drugs Market Size by Application (2019-2024) & ($ Millions) Table 32. APAC Soft Tissue Sarcoma Targeted Drugs Market Size Market Share by Application (2019-2024) Table 33. Europe Soft Tissue Sarcoma Targeted Drugs Market Size by Country (2019-2024) & ($ Millions) Table 34. Europe Soft Tissue Sarcoma Targeted Drugs Market Size Market Share by Country (2019-2024) Table 35. Europe Soft Tissue Sarcoma Targeted Drugs Market Size by Type (2019-2024) & ($ Millions) Table 36. Europe Soft Tissue Sarcoma Targeted Drugs Market Size Market Share by Type (2019-2024) Table 37. Europe Soft Tissue Sarcoma Targeted Drugs Market Size by Application (2019-2024) & ($ Millions) Table 38. Europe Soft Tissue Sarcoma Targeted Drugs Market Size Market Share by Application (2019-2024) Table 39. Middle East & Africa Soft Tissue Sarcoma Targeted Drugs Market Size by Region (2019-2024) & ($ Millions) Table 40. Middle East & Africa Soft Tissue Sarcoma Targeted Drugs Market Size Market Share by Region (2019-2024) Table 41. Middle East & Africa Soft Tissue Sarcoma Targeted Drugs Market Size by Type (2019-2024) & ($ Millions) Table 42. Middle East & Africa Soft Tissue Sarcoma Targeted Drugs Market Size Market Share by Type (2019-2024) Table 43. Middle East & Africa Soft Tissue Sarcoma Targeted Drugs Market Size by Application (2019-2024) & ($ Millions) Table 44. Middle East & Africa Soft Tissue Sarcoma Targeted Drugs Market Size Market Share by Application (2019-2024) Table 45. Key Market Drivers & Growth Opportunities of Soft Tissue Sarcoma Targeted Drugs Table 46. Key Market Challenges & Risks of Soft Tissue Sarcoma Targeted Drugs Table 47. Key Industry Trends of Soft Tissue Sarcoma Targeted Drugs Table 48. Global Soft Tissue Sarcoma Targeted Drugs Market Size Forecast by Regions (2025-2030) & ($ Millions) Table 49. Global Soft Tissue Sarcoma Targeted Drugs Market Size Market Share Forecast by Regions (2025-2030) Table 50. Global Soft Tissue Sarcoma Targeted Drugs Market Size Forecast by Type (2025-2030) & ($ Millions) Table 51. Global Soft Tissue Sarcoma Targeted Drugs Market Size Forecast by Application (2025-2030) & ($ Millions) Table 52. Roche Details, Company Type, Soft Tissue Sarcoma Targeted Drugs Area Served and Its Competitors Table 53. Roche Soft Tissue Sarcoma Targeted Drugs Product Offered Table 54. Roche Soft Tissue Sarcoma Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 55. Roche Main Business Table 56. Roche Latest Developments Table 57. Pfizer Details, Company Type, Soft Tissue Sarcoma Targeted Drugs Area Served and Its Competitors Table 58. Pfizer Soft Tissue Sarcoma Targeted Drugs Product Offered Table 59. Pfizer Main Business Table 60. Pfizer Soft Tissue Sarcoma Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 61. Pfizer Latest Developments Table 62. Johnson & Johnson Details, Company Type, Soft Tissue Sarcoma Targeted Drugs Area Served and Its Competitors Table 63. Johnson & Johnson Soft Tissue Sarcoma Targeted Drugs Product Offered Table 64. Johnson & Johnson Main Business Table 65. Johnson & Johnson Soft Tissue Sarcoma Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 66. Johnson & Johnson Latest Developments Table 67. GSK Plc Details, Company Type, Soft Tissue Sarcoma Targeted Drugs Area Served and Its Competitors Table 68. GSK Plc Soft Tissue Sarcoma Targeted Drugs Product Offered Table 69. GSK Plc Main Business Table 70. GSK Plc Soft Tissue Sarcoma Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 71. GSK Plc Latest Developments Table 72. Teva Pharmaceuticals Details, Company Type, Soft Tissue Sarcoma Targeted Drugs Area Served and Its Competitors Table 73. Teva Pharmaceuticals Soft Tissue Sarcoma Targeted Drugs Product Offered Table 74. Teva Pharmaceuticals Main Business Table 75. Teva Pharmaceuticals Soft Tissue Sarcoma Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 76. Teva Pharmaceuticals Latest Developments Table 77. Celgene Details, Company Type, Soft Tissue Sarcoma Targeted Drugs Area Served and Its Competitors Table 78. Celgene Soft Tissue Sarcoma Targeted Drugs Product Offered Table 79. Celgene Main Business Table 80. Celgene Soft Tissue Sarcoma Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 81. Celgene Latest Developments Table 82. Bristol Myers Squibb Details, Company Type, Soft Tissue Sarcoma Targeted Drugs Area Served and Its Competitors Table 83. Bristol Myers Squibb Soft Tissue Sarcoma Targeted Drugs Product Offered Table 84. Bristol Myers Squibb Main Business Table 85. Bristol Myers Squibb Soft Tissue Sarcoma Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 86. Bristol Myers Squibb Latest Developments Table 87. BeiGene Details, Company Type, Soft Tissue Sarcoma Targeted Drugs Area Served and Its Competitors Table 88. BeiGene Soft Tissue Sarcoma Targeted Drugs Product Offered Table 89. BeiGene Main Business Table 90. BeiGene Soft Tissue Sarcoma Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 91. BeiGene Latest Developments Table 92. Shenzhen Chipscreen Details, Company Type, Soft Tissue Sarcoma Targeted Drugs Area Served and Its Competitors Table 93. Shenzhen Chipscreen Soft Tissue Sarcoma Targeted Drugs Product Offered Table 94. Shenzhen Chipscreen Main Business Table 95. Shenzhen Chipscreen Soft Tissue Sarcoma Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 96. Shenzhen Chipscreen Latest Developments Table 97. Monopar Therapeutics Details, Company Type, Soft Tissue Sarcoma Targeted Drugs Area Served and Its Competitors Table 98. Monopar Therapeutics Soft Tissue Sarcoma Targeted Drugs Product Offered Table 99. Monopar Therapeutics Main Business Table 100. Monopar Therapeutics Soft Tissue Sarcoma Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 101. Monopar Therapeutics Latest Developments Table 102. Akeso Biopharma Details, Company Type, Soft Tissue Sarcoma Targeted Drugs Area Served and Its Competitors Table 103. Akeso Biopharma Soft Tissue Sarcoma Targeted Drugs Product Offered Table 104. Akeso Biopharma Soft Tissue Sarcoma Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 105. Akeso Biopharma Main Business Table 106. Akeso Biopharma Latest Developments List of Figures Figure 1. Soft Tissue Sarcoma Targeted Drugs Report Years Considered Figure 2. Research Objectives Figure 3. Research Methodology Figure 4. Research Process and Data Source Figure 5. Global Soft Tissue Sarcoma Targeted Drugs Market Size Growth Rate 2019-2030 ($ Millions) Figure 6. Soft Tissue Sarcoma Targeted Drugs Sales by Geographic Region (2019, 2023 & 2030) & ($ millions) Figure 7. Soft Tissue Sarcoma Targeted Drugs Sales Market Share by Country/Region (2023) Figure 8. Soft Tissue Sarcoma Targeted Drugs Sales Market Share by Country/Region (2019, 2023 & 2030) Figure 9. Global Soft Tissue Sarcoma Targeted Drugs Market Size Market Share by Type in 2023 Figure 10. Soft Tissue Sarcoma Targeted Drugs in Hospitals Figure 11. Global Soft Tissue Sarcoma Targeted Drugs Market: Hospitals (2019-2024) & ($ Millions) Figure 12. Soft Tissue Sarcoma Targeted Drugs in Oncology Centers Figure 13. Global Soft Tissue Sarcoma Targeted Drugs Market: Oncology Centers (2019-2024) & ($ Millions) Figure 14. Soft Tissue Sarcoma Targeted Drugs in Other Figure 15. Global Soft Tissue Sarcoma Targeted Drugs Market: Other (2019-2024) & ($ Millions) Figure 16. Global Soft Tissue Sarcoma Targeted Drugs Market Size Market Share by Application in 2023 Figure 17. Global Soft Tissue Sarcoma Targeted Drugs Revenue Market Share by Player in 2023 Figure 18. Global Soft Tissue Sarcoma Targeted Drugs Market Size Market Share by Regions (2019-2024) Figure 19. Americas Soft Tissue Sarcoma Targeted Drugs Market Size 2019-2024 ($ Millions) Figure 20. APAC Soft Tissue Sarcoma Targeted Drugs Market Size 2019-2024 ($ Millions) Figure 21. Europe Soft Tissue Sarcoma Targeted Drugs Market Size 2019-2024 ($ Millions) Figure 22. Middle East & Africa Soft Tissue Sarcoma Targeted Drugs Market Size 2019-2024 ($ Millions) Figure 23. Americas Soft Tissue Sarcoma Targeted Drugs Value Market Share by Country in 2023 Figure 24. United States Soft Tissue Sarcoma Targeted Drugs Market Size Growth 2019-2024 ($ Millions) Figure 25. Canada Soft Tissue Sarcoma Targeted Drugs Market Size Growth 2019-2024 ($ Millions) Figure 26. Mexico Soft Tissue Sarcoma Targeted Drugs Market Size Growth 2019-2024 ($ Millions) Figure 27. Brazil Soft Tissue Sarcoma Targeted Drugs Market Size Growth 2019-2024 ($ Millions) Figure 28. APAC Soft Tissue Sarcoma Targeted Drugs Market Size Market Share by Region in 2023 Figure 29. APAC Soft Tissue Sarcoma Targeted Drugs Market Size Market Share by Type in 2023 Figure 30. APAC Soft Tissue Sarcoma Targeted Drugs Market Size Market Share by Application in 2023 Figure 31. China Soft Tissue Sarcoma Targeted Drugs Market Size Growth 2019-2024 ($ Millions) Figure 32. Japan Soft Tissue Sarcoma Targeted Drugs Market Size Growth 2019-2024 ($ Millions) Figure 33. Korea Soft Tissue Sarcoma Targeted Drugs Market Size Growth 2019-2024 ($ Millions) Figure 34. Southeast Asia Soft Tissue Sarcoma Targeted Drugs Market Size Growth 2019-2024 ($ Millions) Figure 35. India Soft Tissue Sarcoma Targeted Drugs Market Size Growth 2019-2024 ($ Millions) Figure 36. Australia Soft Tissue Sarcoma Targeted Drugs Market Size Growth 2019-2024 ($ Millions) Figure 37. Europe Soft Tissue Sarcoma Targeted Drugs Market Size Market Share by Country in 2023 Figure 38. Europe Soft Tissue Sarcoma Targeted Drugs Market Size Market Share by Type (2019-2024) Figure 39. Europe Soft Tissue Sarcoma Targeted Drugs Market Size Market Share by Application (2019-2024) Figure 40. Germany Soft Tissue Sarcoma Targeted Drugs Market Size Growth 2019-2024 ($ Millions) Figure 41. France Soft Tissue Sarcoma Targeted Drugs Market Size Growth 2019-2024 ($ Millions) Figure 42. UK Soft Tissue Sarcoma Targeted Drugs Market Size Growth 2019-2024 ($ Millions) Figure 43. Italy Soft Tissue Sarcoma Targeted Drugs Market Size Growth 2019-2024 ($ Millions) Figure 44. Russia Soft Tissue Sarcoma Targeted Drugs Market Size Growth 2019-2024 ($ Millions) Figure 45. Middle East & Africa Soft Tissue Sarcoma Targeted Drugs Market Size Market Share by Region (2019-2024) Figure 46. Middle East & Africa Soft Tissue Sarcoma Targeted Drugs Market Size Market Share by Type (2019-2024) Figure 47. Middle East & Africa Soft Tissue Sarcoma Targeted Drugs Market Size Market Share by Application (2019-2024) Figure 48. Egypt Soft Tissue Sarcoma Targeted Drugs Market Size Growth 2019-2024 ($ Millions) Figure 49. South Africa Soft Tissue Sarcoma Targeted Drugs Market Size Growth 2019-2024 ($ Millions) Figure 50. Israel Soft Tissue Sarcoma Targeted Drugs Market Size Growth 2019-2024 ($ Millions) Figure 51. Turkey Soft Tissue Sarcoma Targeted Drugs Market Size Growth 2019-2024 ($ Millions) Figure 52. GCC Country Soft Tissue Sarcoma Targeted Drugs Market Size Growth 2019-2024 ($ Millions) Figure 53. Americas Soft Tissue Sarcoma Targeted Drugs Market Size 2025-2030 ($ Millions) Figure 54. APAC Soft Tissue Sarcoma Targeted Drugs Market Size 2025-2030 ($ Millions) Figure 55. Europe Soft Tissue Sarcoma Targeted Drugs Market Size 2025-2030 ($ Millions) Figure 56. Middle East & Africa Soft Tissue Sarcoma Targeted Drugs Market Size 2025-2030 ($ Millions) Figure 57. United States Soft Tissue Sarcoma Targeted Drugs Market Size 2025-2030 ($ Millions) Figure 58. Canada Soft Tissue Sarcoma Targeted Drugs Market Size 2025-2030 ($ Millions) Figure 59. Mexico Soft Tissue Sarcoma Targeted Drugs Market Size 2025-2030 ($ Millions) Figure 60. Brazil Soft Tissue Sarcoma Targeted Drugs Market Size 2025-2030 ($ Millions) Figure 61. China Soft Tissue Sarcoma Targeted Drugs Market Size 2025-2030 ($ Millions) Figure 62. Japan Soft Tissue Sarcoma Targeted Drugs Market Size 2025-2030 ($ Millions) Figure 63. Korea Soft Tissue Sarcoma Targeted Drugs Market Size 2025-2030 ($ Millions) Figure 64. Southeast Asia Soft Tissue Sarcoma Targeted Drugs Market Size 2025-2030 ($ Millions) Figure 65. India Soft Tissue Sarcoma Targeted Drugs Market Size 2025-2030 ($ Millions) Figure 66. Australia Soft Tissue Sarcoma Targeted Drugs Market Size 2025-2030 ($ Millions) Figure 67. Germany Soft Tissue Sarcoma Targeted Drugs Market Size 2025-2030 ($ Millions) Figure 68. France Soft Tissue Sarcoma Targeted Drugs Market Size 2025-2030 ($ Millions) Figure 69. UK Soft Tissue Sarcoma Targeted Drugs Market Size 2025-2030 ($ Millions) Figure 70. Italy Soft Tissue Sarcoma Targeted Drugs Market Size 2025-2030 ($ Millions) Figure 71. Russia Soft Tissue Sarcoma Targeted Drugs Market Size 2025-2030 ($ Millions) Figure 72. Spain Soft Tissue Sarcoma Targeted Drugs Market Size 2025-2030 ($ Millions) Figure 73. Egypt Soft Tissue Sarcoma Targeted Drugs Market Size 2025-2030 ($ Millions) Figure 74. South Africa Soft Tissue Sarcoma Targeted Drugs Market Size 2025-2030 ($ Millions) Figure 75. Israel Soft Tissue Sarcoma Targeted Drugs Market Size 2025-2030 ($ Millions) Figure 76. Turkey Soft Tissue Sarcoma Targeted Drugs Market Size 2025-2030 ($ Millions) Figure 77. GCC Countries Soft Tissue Sarcoma Targeted Drugs Market Size 2025-2030 ($ Millions) Figure 78. Global Soft Tissue Sarcoma Targeted Drugs Market Size Market Share Forecast by Type (2025-2030) Figure 79. Global Soft Tissue Sarcoma Targeted Drugs Market Size Market Share Forecast by Application (2025-2030)
